Bio stocks on road to recovery
Justin Bailey
6 October 2010
Australian Financial Review
According to Sebastian Evans, fund manager at Naos Asset Management, four of five biotechnology stocks could end up turning into billion-dollar companies. Eli Lilly, Roche and Pfizer are companies to watch, with patents for their wonder drugs Viagra and Zoloft set to expire - forcing them to scour the world for a new product. Mr Evans likes Acrux, Nanosonics and ImpediMed as well, with ImpediMed a particular favourite among brokers. Nanosonics is currently waiting for approval from the US Food and Drug Administration for its Trophon EPA product. The firm has also secured a distribution agreement with General Electric?s health division and has a "buy" recommendation from the one broker covering the stock. Acrux is looking to move into AndroGel?s US market and has a implied 44 per cent return over the next year according to broker target price estimates.
- Forums
- ASX - By Stock
- ACR
- a glowing endorsement for axiron
a glowing endorsement for axiron, page-2
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.8¢ |
Change
0.003(5.45%) |
Mkt cap ! $16.86M |
Open | High | Low | Value | Volume |
5.5¢ | 5.8¢ | 5.4¢ | $73.70K | 1.303M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 76865 | 5.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 101900 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 76865 | 0.056 |
1 | 35350 | 0.055 |
1 | 16012 | 0.054 |
1 | 18800 | 0.053 |
1 | 16012 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.058 | 101900 | 2 |
0.059 | 225945 | 1 |
0.060 | 115000 | 1 |
0.061 | 100000 | 1 |
0.062 | 116100 | 2 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |